FRI214 - Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis.

MLA

Alkhouri, Naim, et al. “FRI214 - Baseline Demographics and Clinical Characteristics of Subjects Enrolled in the Phase 3 AURORA Study of Cenicriviroc for the Treatment of Liver Fibrosis Associated with Non-Alcoholic Steatohepatitis.” Journal of Hepatology, vol. 73, Aug. 2020, p. S508. EBSCOhost, https://doi.org/10.1016/S0168-8278(20)31490-2.

APA

Alkhouri, N., Wong, V. W.-S., Jablkowski, M., de Guevara, A. L. L., Sheikh, M., Hodge, A., Elkhashab, M., Strasser, S., Park, G. S., Landgren, H., Tan, B., Massetto, B., Pecoraro, M. L., Seyedkazemi, S., Martins, E. B., Fischer, L., Abdelmalek, M., Tetri, B., & Anstee, Q. (2020). FRI214 - Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis. Journal of Hepatology, 73, S508. https://doi.org/10.1016/S0168-8278(20)31490-2

Chicago

Alkhouri, Naim, Vincent Wai-Sun Wong, Maciej Jablkowski, Alma Laura Ladrón de Guevara, Muhammad Sheikh, Alex Hodge, Magdy Elkhashab, et al. 2020. “FRI214 - Baseline Demographics and Clinical Characteristics of Subjects Enrolled in the Phase 3 AURORA Study of Cenicriviroc for the Treatment of Liver Fibrosis Associated with Non-Alcoholic Steatohepatitis.” Journal of Hepatology 73 (August): S508. doi:10.1016/S0168-8278(20)31490-2.